Collectively, the Donafenib-Alisertib combination suppresses NF-κB signaling by inhibiting p65 activation and nuclear translocation while stabilizing IκBα, mechanistically driving ferroptosis in HCC. Here, NFKB1 is linked to hepatocellular carcinoma.